A systematic review on pharmacokinetic changes in critically ill patients role of extracorporeal, membrane oxygenation

DARU, Journal of Pharmaceutical Sciences

Volumn 19, Issue 5, 2011, Pages 312-321

  Mousavi, S ^a   Levcovich, B ^b   Mojtahedzadeh, M ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b MONASH UNIVERSITY   (Australia)

Author keywords

Extracorporeal membrane oxygenation (ECMO); Pharmacokinetics; Systematic review

Indexed keywords

ALPHA HYDROXYMIDAZOLAM; ALTEPLASE; AMIODARONE; AMPICILLIN; ANALGESIC AGENT; ANTIBIOTIC AGENT; BUMETANIDE; CASPOFUNGIN; CEFOTAXIME; DIAZEPAM; ESMOLOL; FUROSEMIDE; GENTAMICIN; GLYCEROL NITRATE; LORAZEPAM; MIDAZOLAM; MORPHINE; NESIRITIDE; NICARDIPINE; PHENOBARBITAL; PROPOFOL; PROSTAGLANDIN E1; RANITIDINE; SEDATIVE AGENT; SILDENAFIL; THEOPHYLLINE; TOBRAMYCIN; UNINDEXED DRUG; VANCOMYCIN; VORICONAZOLE;

CRITICALLY ILL PATIENT; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG MONITORING; EXTRACORPOREAL OXYGENATION; HUMAN; KIDNEY CLEARANCE; LIVER CLEARANCE; LOW DRUG DOSE; PROTEIN BINDING; REVIEW; SYSTEMATIC REVIEW (TOPIC);

EID: 84455169801     PISSN: 15608115     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (76)

1. Bartlett RH. Extracorporeal life support in the management of severe respiratory failure. Clin Chest Med 2000; 21:555-61.
2. Peek GJ, Sosnowski AW. Extracorporeal membarne oxygenation for pediatric resporatory failure. Brit Med Bulletin 1997; 53:745-56.
3. Wolfson PJ. The development and use of extracorporeal membrane oxygenation in neonates. Ann Thorac Surg 2003; 76:2224-9.
4. Bartlett RH. Extracorporeal oxygenation in infants. Hosp Pract 1984; 19:139-51.
5. Bartlett RH, Gazzaniga AB, Toomasian J, Coran AG, Roloff D, Rucker R, Corwin AG. Extracorporeal membrane oxygenation (ECMO) in neonatal respiratory failure: 100 cases. Ann Surg 1986; 204:236-45.
6. Bennett CC, Davis CF. Evidence-based use of neonatal extracorporeal membrane oxygenation (0ECMO). Current Paediatrics 2003; 13:146-50.
7. Hemmila MR, Rowe SA, Boules TN, Miskulin J, McGillicuddy JW, Schuerer DJ, et al. Extracorporeal life support for severe acute respiratory distress syndrome in adults. Ann Surg 2004; 240(4):595-605.
8. Lewandowski K. Extracorporeal membrane oxygenation for severe acute respiratory failure. Critic Care 2000; 4:156-68.
9. Ombes A, Leprince P, Luyt CE, Bonnet N, Trouillet JL, Leger P, et al. Outcomes and long-term quality-of-life of patients supported by extracorporeal membrane oxygenation for refractory cardiogenic shock. Crit Care Med 2008; 36:1404-11.
10. Pagani FD, Aaronson KD, Swaniker F, Bartlett RH. The use of extracorporeal life support in adult patients with primary cardiac failure as a bridge to implantable left ventricular assist device. Ann Thorac Surg 2001; 71(3(Suppl)):S77-S85.
11. Peek GJ, Moore HM, Sosnowski AW. Extracorporeal Membrane Oxygentaion for adult respiratory failure. Chest 1997; 112:759-64.
12. Mugford M, Elbourne D, Field D. Extracorporeal membrane oxygenation for severe respiratory failure in newborn infants. Cochrane Database Syst Rev 2002; 1:CD001340.
13. Mulla H, Lawson G, Firmin RK, Upton DR. Drug disposition during extracorporeal membrane oxygenation (ECMO). Paediatr Perinat Drug Ther 2001; 4:109-20.
14. Bennett CC, Johnson A, Field DJ; UK Collaborative ECMO Trial Group. A comparison of clinical variables that predict adverse outcome in term infants with severe respiratory failure randomised to a policy of extracorporeal membrane oxygenation or to conventional neonatal intensive care. J Perinat Med 2002; 30:225-30.
15. Hofkosh D, Thompson AE, Nozza RJ, Kemp SS, Bowen A, Feldman HM. Ten years of extracorporeal membrane oxygenation: neurodevelopmental outcome. Pediatrics 1991; 87:549-55.
16. Kolla S, Awad SS, Rich PB, Schreiner RJ, Hirschl RB, Bartlett RH.Extracorporeal life support for 100 adult patients with severe respiratory failure. Ann Surg 1997; 226:544-64.
17. Peek GJ, Mugford M, Tiruvoipati R, Wilson A, Allen E, Thalanany MM, et al. Efficacy and economic assessment of conventional ventilatory support versus extracorporeal membrane oxygenation for severe adult respiratory failure (CESAR): a multicentre randomised controlled trial. Lancet 2009; 374:1351-63.
18. Ala S, Rouini MR, Mojtahedzadeh M, Khalili H, Nayebpour M, Najafi A, Khaji S. Pharmacokinetic of IV lidocaine infusion in post acute myocardial infarction. The Journal of Faculty of Medicine at TUMS 2005; 62:115-20.
19. Mojtahedzadeh M, Sadray S, Hadjibabaie M, Fasihi M, Rezaee S.Determination of Theophylline Clearance after Cimetidine Infusion in Critically Ill Patients. J Infuse Nurse 2003; 26:234-8.
20. Mojtahedzadeh M, Salehifar E, Vazin A, Mahidiani H, Najafi A, Tavakoli M, Nayebpour M, Abdollahi M. Comparison of Hemodynamic and Biochemical Effects of Furosemide by Continuous Infusion and Bolus in ICU. J Infuse Nurse 2004; 27:255-61.
21. Sabz Ghabaei AM, Mojtahed Zadeh M, Tajer Zadeh H, Asasi N, Ganji MR, Mohagheghi A, Gholami Kh, Hadavand N.Pharmacokinetic Behavior of Amikacin in 31 Iranian Critically Ill Septic Patients. Daru 2003; 10:111-9.
22. Sohrevardi SM, Mojtahedzadeh M, Sadri A, Najafi A. The value of Aminophylline Dosing Based on Pharmacokinetic Variables in Critically Ill Patients. Journal of Medical council IR 2004; 22:28-31.
23. Hadidi E, Mojtahedzadeh M, Rouini MR, Eftekhar B, Abdollahi M, Najafi A, Khajavi MR, Rezaee S, Ghaffari R, Afshar M. The Evaluation of the possible effect of PEEP on Pharmacokinetic of Phenytoin in Patients with Acute Brain Injury under Mechanical Ventilation. Daru 2005; 1374-81.
24. Hadavand N, Mojtahedzadeh M, Sadray S, Shariat Moharreri R, Shafaghi B, Khajavi MR, Salari P. Phrmacokinetic Behavior of Theophylline Following PEEP in Critically Ill Patients. IJPR 2004; 3:35-40.
25. Mojtahedzadeh M, Ala S. A study of Lidocaine Pharmacokinetic Behavior Following Endotracheal Administration in ICU. Journal of Medical Faculty Guilan University of Medical Sciences 2004; 13:9-14.
26. Najafi A, Samadani M, Mojtahedzadeh M, Khajavi MR, Eftekhar B, Rouni MR, et al. Pharmacokinetic Behavior of Phenytoin following Positive end Expiratory Pressure in Traumatic Brain Injury Patients with Acute Lung Injury. Journal of lranian society Anaesthesiology 2004; 24:6-15.
27. Najafi A, Samdani M, Mojtahedzadeh M. Pharmacokinetic Behavior of Phenytoin Following PEEP in TBI. The Journal of Faculty of Medicine at TUMS 2005; 62:162-7.
28. Najafi A, Shariat Moharreri R, Mojtahedzadeh M, Khajavi MR, Hadavand N, Sadray S. The Effect of Positive End Expiratory Pressure on Pharmacokinetic Behavior of Aminophylline in ALI. Journal of lranian society of Anaesthesiology 2004; 24:26-33.
29. Anderson H, Coran A, Dongowski R, Ha H, Bartelet R. Extracellular fluid and total body water changes in neonates undergoing Extracorporeal membrane oxygenation. J Paediatric surg 1992; 27:1003-8.
30. Buck ML. Pharmacokinetic changes during extracorporeal membrane oxygenation: implications for drug therapy of neonates. Clin Pharmacokinet 2003;42:403-17.
31. Green TP. The effect of extracorporeal membrane oxygenation on the biodisposition of drugs. Curr Opin Pediatr 1992; 4:473.
32. Mehta NM, Halwick DR, Dodson BL, Thompson JE, Arnold JH. Potential drug sequestration during extracorporeal membrane oxygenation: results from an ex vivo experiment. Intensive Care Med 2007; 33:1018-24.
33. Mulla H, Lawson G, Woodland ED, Peek GJ, Killer H, Firmin RK, et al. Effect of Neonatal extracorporeal membrane oxygenation circuits on drug disposition. Curr Ther Res 2000; 61:838-48.
34. Noerr B. ECMO and pharmacotherapy.Neonatal Netw 1996; 15:23-31.
35. Barry J, Egan TD, Sandoval NF, Zomorodi K, Cohane C, Gambus PL, Shafer SL. Propofol dosing regimens for ICU sedation based upon an integrated pharmacokinetic-pharmacodynamic model. Anesthesiology 2001; 95: 324-33.
36. Johnston A, Steiner L, O'Connell M, Chantfield D, Menon D. Pharmacokinetics and pharmacodynamic od dopamine and norepinephrine in critically ill head-injured patients. Intens Care Med 2004; 30: 45-50.
37. Roos J, Bulita J, Lipman J, Kirkpatrick C. Pharmacokinetic-pharmacodynamic rational for cefepim dosing regimens in intensive care units. J Antimic Chemo 2006; 58: 987-993.
38. Mar-Fernandez M, Rivella N, Calvo M, Dominguez-Gil A. Pharmacokinetic/pharmacodynamic analysis of vancomycin in ICU patients. Intens Care Med 2007; 33:279-285.
39. Buck ML. Pharmacokinetic Changes during Extracorporeal Membrane Oxygenation: Implications for Drug Therapy of Neonates. Clin Pharmacokinet 2003; 42(5):403-17.
40. Haffajee CL. Clinical pharmacokinetics of amiodarone. Clin Cardiol 1987; 10:16-19.
41. Shevde K, DeBois WJ. Pro: Pulsatile flow is preferable to non-pulsatile flow during cardiopulmonary bypass. J Cardiothorac Anesth 1987; 1:165-8.
42. Many M, Soroff HS, Birtwell WC, Giron F, Wise H, Deterling RA Jr. The physiologic role of pulsatile and nonpulsatile blood flow. Arch Surg 1968; 97:917-23.
43. Wearden P, Morell V, Munoz R. Extracorporeal Membrane Oxygenation and Drug Clearance. Handbook of Pediatric Cardiovascular Drugs 2008; 215-25.
44. Mulla H, Lawson G, Woodland ED, Peek GJ, Killer H, Firmin RK, et al. Effects of neonatal extracorporeal membrane oxygenation circuits on drug disposition. Curr Ther Res 2000; 61:838-48.
45. Wildschut ED, Ahsman MJ, Allegaert K, Mathot R, Tibboel D. Determinants of drug absorption in different ECMO circuits. Intensive Care Med 2010; 36:20109-16.
46. Bhatt-Mehta V, Annich G. Sedative clearance during extracorporeal membrane oxygenation. Perfusion 2005; 20:309.
47. Dagan O, Klein J, Bohn D, Koren G. Effect of extracorporeal membrane oxygenation on morphine pharmacokinetics in infants. Crit Care Med 1994; 22:1092-101.
48. DeBerry B, Lynch J, Chernin J, Zwischenberger J, Chung D. A survey for pain and sedation medications in pediatric patients during extracorporeal membrane oxygenation. Perfusion 2005; 20:139-43.
49. Ahsman MJ, Hanekamp M, Wildschut ED, Tibboel D, Mathot RA. Population Pharmacokinetics of Midazolam and Its Metabolites during Venoarterial Extracorporeal Membrane Oxygenation in Neonates. Clin Pharmacokinet 2010; 46:407-13.
50. Crill C, Bugnitz M, Hak E. Evaluation of gastric PH and guaiac measurements in neonates recieving acid suppression therapy during Extracorporeal Membrane Oxygenation. Pharmacotherapy 2004; 24:1130-6.
51. Wells TG, Heulitt MJ, Taylor BJ, Faselus JW, Kearns G. Pharmacokinetics and pharmacodynamics of ranitidine in neonates treated with extracorporeal membrane oxygenation. J Clin Pharmacol 1998; 38:402-7.
52. Amaker RD, DiPiro JT, Bhatia J. Pharmacokinetics of vancomycin in critically ill infants undergoing extracorporeal membrane oxygenation. Antimicrob Agents Chemother 1996; 40:1139.
53. Hoie E, Swigart S, Leuschen M, Willett L, Bolam D, Goodrich P, et al. Vancomycin pharmacokinetics in infants undergoing extracorporeal membrane oxygenation. Clin Pharm 1990; 9:711-5.
54. Buck ML. Vancomycin pharmacokinetics in neonates receiving extracorporeal membrane oxygenation. Pharmacotherapy 1998; 18:1082-806.
55. Mulla H, Pooboni S. Population pharmacokinetics of vancomycin in patients receiving extracorporeal membrane oxygenation. Br J Clin Pharmacol 2005; 60:265-75.
56. Wu CH. Pharmacokinetics and Posology of Vancomycin in Adults Receiving ECMO.NTUR 2007: Item 246246/55435.
57. Bhatt-Mehta V, Johnson CE, Schumacher RE. Gentamicin pharmacokinetics in term neonates receiving extracorporeal membrane oxygenation. Pharmacotherapy 1992; 12:28-32.
58. Southgate M, DiPiro J, Robertson A. Pharmacokinetics of Gentamicin in Neonates on Extracorporeal Membrane Oxygenation. Antimicrob Agents Chemother 1989; 33:817-9.
59. Cohen P, Collart L, Prober C, Fischer A, Blaschke T. Gentamicin pharmacokinetics in neonates undergoing Extracorporeal membrane oxygenation. Pediatr Infect Dis 1990; 9:562-6.
60. Dodge WF, Jelliffe RW, Zwischenberger JB, Bellanger RA, Hokanson JA, Snodgrass WR. Population pharmacokinetic models: effect of explicit versus assumed constant serum concentration assay error patterns upon parameter values of gentamicin in infants on and off extracorporeal membrane oxygenation. Ther Drug Monit 1994; 16:552-9.
61. Ashman MJ, Wildschut E, Tibboel D, Mathot R. Pharmacokinetics of Cefotaxime and Desacetylcefotaxime in Infants during Extracorporeal Membrane Oxygenation. Antimicrob Agents Chemother 2010; 54:1734-41.
62. Wildschut E, Hoog M, Ahsman MJ, Tibboel D, Osterhous A, Fraiij P. Plasma Concentrations of Oseltamivir and Oseltamivir Carboxylate in Critically Ill Children on Extracorporeal Membrane Oxygenation Support. Plos One 2010; 5:e10938.
63. Spriet I, Annaert P, Meersseman P, Hermans G, Meersseman W, Verbesselt R, Willems L.Pharmacokinetics of caspofungin and voriconazole in critically ill patients during extracorporeal membrane oxygenation. J Antimicrob Chemother 2009; 63:767-70.
64. Mulla H, Nabi F, Nichani S, Lawson G, Firmin RK, Upton D. Population pharmacokinetics of theophylline during paediatric extracorporeal membrane oxygenation. Br J Clin Pharmacol 2002; 55:23-31.
65. Moller J, Gilman J, Kearns G, Sussmane J, Raszynsky J, Wolfsdorf J, et al. Effect of extracorporeal membrane oxygenation on tobramycin pharmacokinetics in sheep. Crit Care Med 1992; 20:1454-8.
66. Jeroen P, Brian A, Sinno S, Donald U, Dick T. Morphine pharmacokinetics during venoarterial extracorporeal membrane oxygenation. Intensive Care Med 2005; 31:257-63.
67. Geiduschek JM, Lynn AM, Bratton SL, Sanders JC, Levy FH, Haberkern CM, et al. Morphine pharmacokinetics during continuous infusion of morphine sulfate for infants receiving extracorporeal membrane oxygenation. Crit Care Med 1997; 25:360.
68. Mulla H, McCormack P, Lawson G, Firmin RK, Upton DR. Pharmacokinetics of midazolam in neonates undergoing extracorporeal membrane oxygenation. Anesthesiology 2003; 99:275.
69. Elliot E, Buck ML. Phenobarbital Dosing and Pharmacokinetics in a Neonate Receiving Extracorporeal Membrane Oxygenation. Ann Pharmaother 1999; 33:419-22.
70. van der Vorst MM, Wildschut E, Houmes RJ, Gischler SJ, Kist-van Holthe JE, Burggraaf J, van der Heijden AJ, Tibboel D. Evaluation of furosemide regimens in neonates treated with extracorporeal membrane oxygenation. Crit Care 2006; 10:R168.
71. Wells T, Fasules J, Taylor B, Kearns G. Pharmacokinetics and pharmacodynamics of bumetanide in neonates treated with extracorporeal membrane oxygenation. The J Pediatr 1992; 121:974-80.
72. Ahsman M. Determinants of pharmacokinetic variability during extracorporeal membrane oxygenation [PhD Thesis]. Optima Grafische Communicatie, Rotterdam: the Netherlands: 2010.
73. Glover ML, Camacho MT, Wolfsdorf J. The use of alteplase in a newborn receiving extracorporeal membrane oxygenation. Ann Pharmaother 1999; 33(4):416-9.
74. Stone DM, Frattarellic DAC, Karthikegan S, Johnson YR. Altered prostaglandin E1 dosage during Extracorporeal Membrane Oxygenation in a newborn with ductal dependent congenital heart disease. Pediatr Cardiol 2006; 27:360-63.
75. McBride B, White M, Campbell M, Frey B. Nicardipine to control neonatal hypertension during extracorporeal membrane oxygen support. Ann Pharmaother 2003; 37:667-70.
76. Watt K, Li JS, Benjanin DK, Cohen-Wolkoweiz M. Pediatric cardiovascular drug dosing in critically ill children and extracorporeal membrane oxygenation. J Cardiovasc Pharmacol 2011; 58:126-32.